Aprea Therapeutics, Inc. (APRE)
EBITDA Growth
-10.89%
Quarterly · Period ending:
APRE EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-10.89%period ending
Latest reported-10.89%period ending
APRE Quarterly EBITDA YoY % (-144.38% → -10.89%)
Year-over-year change
High-resolution chart · PNG
APRE ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -10.8898% | |
| 16.4172% | |
| 15.1995% | |
| 21.474% | |
| 6.676% | |
| -40.0614% | |
| 15.9643% | |
| -17.9595% | |
| -6.3174% | |
| 35.9756% | |
| -40.8525% | |
| 19.1824% | |
| 85.4395% | |
| 44.3729% | |
| 68.2536% | |
| 57.7598% | |
| -119.6393% | |
| 22.1557% | |
| 45.7227% | |
| 22.9498% | |
| 29.3949% | |
| 14.3258% | |
| 2.4272% | |
| -70.1605% | |
| -144.2179% | |
| -169.5258% | |
| -196.451% | |
| -144.3787% |